{"id":116265,"date":"2005-04-05T12:52:00","date_gmt":"2005-04-05T16:52:00","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/phase-i-clinical-trial-for-advanced-colon-and-pancreatic-cancer-opens-in-new-york-using-rexin-g-the-worlds-first-tumor-targeted-gene-delivery-vector\/"},"modified":"2005-04-05T12:52:00","modified_gmt":"2005-04-05T16:52:00","slug":"phase-i-clinical-trial-for-advanced-colon-and-pancreatic-cancer-opens-in-new-york-using-rexin-g-the-worlds-first-tumor-targeted-gene-delivery-vector","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/phase-i-clinical-trial-for-advanced-colon-and-pancreatic-cancer-opens-in-new-york-using-rexin-g-the-worlds-first-tumor-targeted-gene-delivery-vector\/","title":{"rendered":"Phase I Clinical Trial for Advanced Colon and Pancreatic Cancer Opens in New York Using Rexin-G, the World&#8217;s First Tumor-Targeted Gene Delivery Vector"},"content":{"rendered":"<p class=\"s2pred\"><strong>NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong><\/p>\n<p>LOS ANGELES, Calif. &#8212; (SEND2PRESS NEWSWIRE) &#8212; Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. <\/p>\n<p> In 2003, Rexin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Rexin-G as an effective treatment for pancreatic cancer. <\/p>\n<p> Six out of six initial patients with advanced pancreatic cancer responded favorably to Rexin-G, as evidenced by significant shrinkage and\/or disappearance of metastatic tumor nodules, or stabilization of disease, relief from pain, weight gain and extension of over-all survival time, without experiencing the side effects generally associated with standard chemotherapy. Clinical trials of Rexin-G have now been expanded to include patients with colorectal cancer that has spread to the liver.<\/p>\n<p> Epeius Biotechnologies Corporation recently secured exclusive licensing rights to its Pathotropic (disease-seeking) targeting platform, including the FDA-approved Targeted Delivery System (TDS) that enables its lead product, Rexin-G, to seek and destroy metastatic tumors. Following the success of &#8220;compassionate use&#8221; clinical trials using Rexin-G for metastatic pancreatic cancer, Epeius Biotechnologies has completed the transition from an academic start-up to a specialty pharmaceutical company, and has gained the financial support needed to expand the scope of its landmark clinical trials in the United States. <\/p>\n<p> In a statement to the press, Dr. Frederick Hall, President and CEO of Epeius said that, &#8220;We are now in an excellent position to complete our mission: to develop our business plan in an exemplary manner, and to commercialize our high-value lead product for the benefit of cancer patients worldwide.&#8221;<\/p>\n<p> About Epeius <\/p>\n<p> Epeius Biotechnologies Corporation is a privately held biopharmaceutical company that was formed to develop and commercialize the first truly effective Targeted Delivery System (TDS) that can be injected directly into a vein to deliver genetic medicine preferentially to cancerous tumors that have spread throughout the body (metastatic cancer), without eliciting systemic side effects or organ damage. <\/p>\n<p> More information: <a href=\"http:\/\/www.epeiusbiotech.com\">www.epeiusbiotech.com<\/a>.<\/p>\n<p>News issued by: Epeius Biotechnologies Corporation<\/p>\n<p> # # # <\/p>\n<p><small>Original Story ID:  (237) :: 2005-04-0405-001<\/small><\/p>\n<p><small>Original Keywords: Epeius Biotechnologies Corporation, Rexin-G, Rexin G, Dr. Frederick L. Hall, clinical trial, FDA approval, Orphan Drug, tumor-targeted gene delivery system, vector, metastatic tumor nodules, advanced pancreatic cancer, new york news, Targeted Delivery System (TDS), biotech newswire, biotechnology, medtech Epeius Biotechnologies Corporation   <\/small><\/p>\n<p class=\"s2pred\"><strong>NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong> | Published: 2005-04-05 12:52:00<\/p>\n","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES, Calif. &#8212; (SEND2PRESS NEWSWIRE) &#8212; Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. In 2003, Rexin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Rexin-G as an effective treatment for pancreatic cancer.<\/p>\n","protected":false},"author":9780,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"singles-wide.php","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19937],"tags":[],"class_list":["post-116265","post","type-post","status-publish","format-standard","hentry","category-press-releases-archive","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":556,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/116265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/9780"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=116265"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/116265\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=116265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=116265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=116265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}